Minimal Residual Disease in Myeloma Suggested as Clinical Trial Endpoint, but Experts Disagree
Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study…
Myeloma
Janssen Seeks to Expand Darzalex Use for Multiple Myeloma Patients
Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include…
In Heavily Treated Myeloma Patients, Selinexor-Dexamethasone Combo Shows Positive Results
Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results…
Survival of Younger Myeloma Patients Influenced by Marriage and Insurance, not Ethnicity, Study Finds
With advances in treatment for multiple myeloma, some studies have reported improved survival rates, especially among young white patients and, to a lesser extent, in patients…
Myeloma Patients on Darzalex Combination Treatment Fared Better in Clinical Trial
Adding Darzalex (daratumumab) to the treatment of multiple myeloma with Velcade (bortezomib) and dexamethasone significantly improved progression-free survival in a clinical trial of patients who…
German Agency Questions Benefit of Empliciti Reported in Multiple Myeloma Study
Empliciti (elotuzumab), a monoclonal antibody, is approved in both the U.S. and Europe as a treatment, in combination with Revlimid (lenalidomide) and Decatron (dexamethasone), for multiple myeloma patients who…
Biotech Companies Partner with Memorial Sloan Kettering to Develop Multiple Myeloma Immunotherapy Program
Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center…
Relapsed, Refractory Multiple Myeloma Progression Free Survival Prolonged with Drug Combo
Elotuzumab in combination with bortezomib and dexamethasone prolongs the progression free survival of patients with relapsed or refractory multiple myeloma (RRMM), according to…
MMRF, University of Michigan to Begin Personalized Multiple Myeloma Profiling Initiative
The Multiple Myeloma Research Foundation (MMRF) and the University of Michigan have partnered to provide multiple myeloma patients and their doctors access to…
Myeloma Therapies Advancing Rapidly, Says Expert at Sloan Kettering
In a video posted on Healio’s Hematology-Oncology page, Dr. Ola Landgren, chief of the myeloma service at Memorial Sloan Kettering Cancer Center…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML